PRESS RELEASE
News
-
-
-
-
PRESS RELEASE
Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides
NanoViricides, Inc. announces design completion of adaptive clinical trial protocol for MPox Virus treatment. Trial to evaluate dosing regimen, safety, and effectiveness in 80 patients -
-
-
PRESS RELEASE
There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate
NanoViricides, Inc. announces advancing lead candidate NV-387 into Phase II clinical development for MPox. Protocol development and site addition underway in the DRC. Focus on antiviral drug against MPox/Smallpox -
-
-
PRESS RELEASE
With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan
NanoViricides, Inc. announces the effectiveness of broad-spectrum antiviral drug NV-387 against COVID variants and Bird Flu, positioning it well for pandemic preparedness
